Nls pharmaceutics and kadimastem announce binding term sheet to merge

The proposed transaction will create a nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing kadimastem's allogeneic cell therapy platform each of kadimastem and nls pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares zurich, switzerland and ness ziona, israel / accesswire / july 29, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp) ("nls"), a biopharmaceutical company.
NLSP Ratings Summary
NLSP Quant Ranking